Who is sponsoring NCT04370379?

NCT04370379 is sponsored by Innovent Biologics (Suzhou) Co. Ltd..

What drugs are being tested in NCT04370379?

Interventions in NCT04370379: IBI302 (the first dose level), IBI302 (the second dose level), Aflibercept.

What condition does NCT04370379 study?

NCT04370379 studies Neovascular Age-related Macular Degeneration.

Is NCT04370379 still recruiting?

NCT04370379 is currently completed. Last updated 11 November 2021.

Last reviewed 2021-11-11 · How we verify

NCT04370379

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Completed Phase 1 Last updated 11 November 2021

What this trial tests

Phase 1 trial testing IBI302 (the first dose level) in Neovascular Age-related Macular Degeneration in 18 participants. Completed in 8 May 2021.

Timeline

28 May 2020

Primary endpoint
30 April 2021

8 May 2021

Quick facts

Lead sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	28 May 2020
Primary completion	30 April 2021
Estimated completion	8 May 2021
Sites	1 location across China

Drugs / interventions tested

IBI302 (the first dose level) — full drug profile →
IBI302 (the second dose level) — full drug profile →
Aflibercept (AFLIBERCEPT) — full drug profile →

Conditions studied

Neovascular Age-related Macular Degeneration — all drugs for Neovascular Age-related Macular Degeneration →

Sponsor

Innovent Biologics (Suzhou) Co. Ltd. — full company profile →

Who can join

50 and older, any sex, with Neovascular Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD).
Sarkar A, Junnuthula V, Dyawanapelly S. · · 2021 · cited 31× · PMID 34638935 · DOI 10.3390/ijms221910594
Ocular Delivery of Therapeutic Agents by Cell-Penetrating Peptides.
Nhàn NTT, Maidana DE, Yamada KH. · · 2023 · cited 25× · PMID 37048144 · DOI 10.3390/cells12071071
Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy.
Huang X, Zhang L, Fu Y, Zhang M, et al · · 2023 · cited 3× · PMID 37288355 · DOI 10.3389/fbioe.2023.1199922

Verify or expand the search:

Other recruiting trials for Neovascular Age-related Macular Degeneration

Currently open trials in the same condition.

NCT07275840 — A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD · Phase 2 · recruiting
NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
NCT07053358 — Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients · EARLY_PHASE1 · recruiting
NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
NCT06495918 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- R · Phase 3 · active not recruiting

Other Innovent Biologics (Suzhou) Co. Ltd. trials

Trials by the same sponsor.

NCT07502534 — A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers · Phase 1 · not yet recruiting
NCT07469800 — Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity · Phase 3 · not yet recruiting
NCT07473960 — IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia · Phase 3 · recruiting
NCT07483567 — IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastri · Phase 2 · not yet recruiting
NCT07483554 — IBI343 in Combination Therapy for Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04370379 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Innovent Biologics (Suzhou) Co. Ltd.
Last refreshed: 11 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04370379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing